Tirzepatide vs Semaglutide
Both FDA-approved for weight loss, Zepbound (tirzepatide) typically shows higher weight loss results than Wegovy (semaglutide), but Wegovy has more long-term safety data.
See how patient-reported experiences compare across effectiveness, side effects, and costs.
Prices re-read November 18, 2026
Zepbound costs $1,259 a month, month to month at RxION Health, the cheapest verified Zepbound price among the providers our tracker re-read in the last 36 hours. Wegovy costs $349 every 4 weeks (about $378.08 a month) at NovoCare / Wegovy Direct, the cheapest verified Wegovy price among the providers our tracker re-read in the last 36 hours. Compounded tirzepatide injections start at $118 a month, month to month, at FlatRx; the cheapest month-to-month prices are $118 at FlatRx, $129 at Eden and $129 at Embody among the 43 providers whose tirzepatide prices our tracker re-read in the last 36 hours. Compounded semaglutide injections start at $79 a month, month to month, at Embody; the cheapest month-to-month prices are $79 at Embody, $99 at Eden and $99 at FlatRx among the 45 providers whose semaglutide prices our tracker re-read in the last 36 hours. Compounded medication is not FDA-approved. Prices read on each provider's own site on November 18, 2026.
$1,259 a month, month to month
at RxION HealthRead on November 18, 2026 at 12:50 UTC on tryrxion.com/weight-management/zepbound
Cheapest verified Zepbound price, as the provider words it.
$349 every 4 weeks (about $378.08 a month)
at NovoCare / Wegovy DirectRead on November 18, 2026 at 12:41 UTC on novocare.com/pharmacy.html
Cheapest verified Wegovy price, as the provider words it.
Cheapest month-to-month prices, one per provider, ordered by price alone (43 providers re-read).
Cheapest month-to-month prices, one per provider, ordered by price alone (45 providers re-read).
Read by our tracker on each provider’s own site. AllGLP1 may earn a commission if you sign up through a link above; it never changes the prices shown or their order.
Side-by-side comparison of reported experiences
| Feature | Zepbound | Wegovy | Source Notes |
|---|---|---|---|
| Active Ingredient | Tirzepatide | Semaglutide | Different molecules, different mechanisms |
| Mechanism | Dual GIP/GLP-1 | GLP-1 only | Tirzepatide targets two receptors |
| Typical Weight Loss | 20.2% | 13.7% | SURMOUNT-5 head-to-head trial (72 weeks) |
| Max Dose | 15mg weekly | 2.4mg weekly | Per prescribing information |
| Brand Cost (Self-Pay) | $399-549/mo (vials) | $349-499/mo (NovoCare) | 2026 self-pay pricing programs |
| Compounded Cost | $250-450/mo | $175-400/mo | Verified provider pricing Learn more → |
| FDA Approval | 2023 | 2021 | Weight loss indication dates |
| Cardiovascular Data | Ongoing | 20% MACE reduction | SELECT trial proven benefit for Wegovy |
Different molecules, different mechanisms
Tirzepatide targets two receptors
SURMOUNT-5 head-to-head trial (72 weeks)
Per prescribing information
2026 self-pay pricing programs
Weight loss indication dates
SELECT trial proven benefit for Wegovy
Figures in this table were typed when the page was written and may be out of date; today's verified prices are in the cost box above.
Data from the SURMOUNT-5 (The New England Journal of Medicine (2025))
The SURMOUNT-5 trial was the first large-scale, head-to-head Phase 3b clinical study directly comparing tirzepatide (Zepbound) and semaglutide (Wegovy) for weight loss in adults with obesity or overweight with at least one weight-related comorbidity (excluding diabetes).
| Comparison Metric | Zepbound | Wegovy |
|---|---|---|
| Average Weight Loss (%) | 20.2% | 13.7% |
| Total Body Weight Loss (lbs) | approx. 50 lbs | approx. 33 lbs |
| Lost >15% Body Weight | 71.3% | 45.1% |
| Lost >20% Body Weight | 52.5% | 28.1% |
| Lost >25% Body Weight | 33.1% | 13.6% |
"In this direct head-to-head comparison, tirzepatide (Zepbound) was found to be superior to semaglutide (Wegovy) for weight reduction at 72 weeks. While both medications are highly effective, Zepbound achieved nearly 50% more weight loss on average than Wegovy in this specific study population."
Results were statistically significant (p < 0.001) across all primary endpoints.
Latest verification performed January 2026.
Answer these 3 questions to see your best match:
Take our 90-second quiz for personalized provider recommendations ranked by your insurance + budget.
Start QuizPatient-reported side effect patterns
Drawing from patient-reported strategies
Real questions from Zepbound users
Common questions from Zepbound users
Not sure which is right for you?
🎯Take Our 2-Minute Quiz